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Abstract 
Cancers of the small bowel are relatively rare and account for approximately 1–2% of all 
gastrointestinal neoplasms. The most common histologic subtype – adenocarcinoma – 
constitutes 40% of all cases. These cancers generally present with vague abdominal 
discomfort and are often diagnosed at a late stage and carry a poor prognosis. The 
treatment of choice of early-stage small bowel adenocarcinoma is surgical resection. No 
standard treatment protocol has been defined for unresectable or metastatic disease. 
Here, we report a case of a 56-year-old woman who presented with unexplained iron 
deficiency anemia. Extensive initial studies with serial CT scans of the abdomen, 
esophagogastroduodenoscopy, small bowel capsule endoscopy and colonoscopy were 
noncontributory. She was later found to have a metastatic small bowel adenocarcinoma 
and treated with palliative chemotherapy. She achieved a modest response to the 
treatment. Interestingly, in our case, the sole presentation was unexplained iron 
deficiency anemia. Physician’s awareness regarding the possibility of small bowel cancer 
especially in the setting of iron deficiency and its workup has been emphasized. This 
enhances the chance of early detection and hence better survival. 
 
Background 
Malignant neoplasms of the small bowel are exceedingly rare and account for only 2% 
of all gastrointestinal cancers [1]. The most commonly occurring histological subtypes are 
adenocarcinomas (40%), malignant carcinoid tumors (36%), lymphomas and sarcomas Case Rep Oncol 2011;4:458–463 
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[1]. The peak incidence of small bowel tumor is in the fifth and sixth decade of life with a 
higher prevalence rates in black population than in whites (10.6 vs. 5.6 per million 
populations) [3]. At present, there are no good screening methods for small bowel 
adenocarcinoma (SBA). Initial symptoms of SBA are vague, nonspecific, and hence 
appropriate tests are not ordered. The current methodologies for examining the small 
bowel have proved inadequate. In spite of recent advances in radiographic imaging and 
endoscopy techniques, early detection of neoplasms of the small intestine is still low [4]. 
Therefore, the diagnosis of small bowel cancers is often delayed, contributing to the poor 
prognosis. 
Epidemiologically, SBAs are more common at the proximal end. Approximately 50% 
of the cases arise in the duodenum, 30% in the jejunum, and 20% in the ileum. Genetic 
analyses suggest K-ras mutation and p53 overexpression are common in SBA as they are 
in colorectal carcinoma [5, 6]. 
To our knowledge, little is known about the clinical characteristics, treatment 
modalities and prognosis of patients with SBA. This is mainly due to the rarity of this 
cancer. Maglinte et al. [7] have shown that there is a 8.2-month delay in the diagnosis of 
SBA, due to its vague symptoms like nonspecific abdominal discomfort. This is attributed 
to the failure of the physician to order the appropriate tests. Therefore, it is very 
important to identify the cause of unexplained iron deficiency anemia in middle-aged 
patients as it could possibly be a harbinger for SBA. Here, we report a case of SBA 
presenting with unexplained iron deficiency anemia for a prolonged period, with classical 
noncontributory radiography, gastroduodenoscopy, small bowel capsule endoscopy and 
colonoscopy. 
Case Report 
A 56-year-old woman with a one-year history of unexplained iron deficiency anemia despite 
extensive gastrointestinal workup was admitted with dizziness and shortness of breath. She was found to 
have severe anemia (hemoglobin 5 g/dl) in the emergency room. Her past medical history includes 
chronic smoking, hemoglobin C trait and hypertension which was diet controlled. She denied any 
recent weight loss, constipation, melena or hematemesis. One year prior to her admission, her upper 
gastrointestinal endoscopy and colonoscopy as a workup for iron deficiency anemia were normal. She 
later had a video-assisted capsule endoscopy which was also unremarkable. Interestingly, CT scan of 
abdomen and pelvis with oral and intravenous contrast 4 months and 1 year prior to her admission 
were normal as well. 
On physical examination, she was afebrile with stable vital signs. She appeared cachectic with severe 
pallor of the conjunctiva. Physical examination was otherwise unremarkable. Her abdomen was soft 
without any rebound tenderness and did not reveal any organomegaly. Laboratory tests showed 
(reference range in parentheses) severe microcytic hypochromic anemia with hemoglobin of 5.0 g/dl 
(11.7–16.1 g/dl), hematocrit of 15.9% (37–51%), mean corpuscular volume of 66.5 fl (80–101 fl), platelet 
count of 546 × 10
9/l (130–450 × 10
9/l), serum ferritin of 6.28 ng/ml (11–264 ng/ml), transferrin of 237 
mg/dl (250–380 mg/dl), total iron binding capacity of 297 μg/dl (240–450 μg/dl), vitamin B12 of 540 
pg/ml (239–931 pg/ml), reticulocyte count of 2.9% (0.5–2.5%) and a transferrin saturation of 4%. There 
was no evidence of hemolysis as bilirubin was normal with normal lactate dehydrogenase of 354 IU/l 
(313–618 IU/l) and a normal haptoglobin level of 214 mg/dl (43–212 mg/dl). She had a normal serum 
CEA level of 1.3 ng/ml (0–3.0 ng/ml). 
Subsequently she developed severe nausea with projectile vomiting. CT scan of abdomen and pelvis 
showed a small bowel lesion measuring about 4.1 cm in length with thickening of the wall and 
narrowing of the lumen of the involved segment (fig. 1). A long distended loop of small bowel was seen 
in the left abdomen and pelvis secondary to the obstructing lesion in the right lower quadrant. No focal Case Rep Oncol 2011;4:458–463 
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hepatic lesions or any mesenteric or omental involvement were seen. Small bowel follow-through with 
barium showed an irregular filling defect in the jejunum suspicious for malignancy (fig. 2). She 
underwent resection of the jejunum which revealed a tumor of the small intestine with 4.5 cm in the 
greatest dimension (fig. 3). A separate tumor mass in the mesentery was seen. Pathology revealed 
moderately differentiated adenocarcinoma with involvement of the entire thickness of the intestinal 
wall. Six out of nine lymph nodes dissected were positive for metastatic carcinoma. Metastatic workup 
with CT scan of chest, abdomen and pelvis with oral and intravenous contrast revealed interval 
development of multiple hepatic lesions measuring about 1.5–2.0 cm with partial small bowel resection 
and without any evidence of bowel obstruction. Genetic studies of the specimen revealed that it had K-
ras wild type mutation. She was started on palliative chemotherapy with a modified FOLFOX-6 regimen 
comprising leucovorin, oxaliplatin and 5-flurouracil for a total of12 cycles. She tolerated chemotherapy 
well except for grade 1 oxaliplatin-induced peripheral neuropathy. She had a stable disease for over 6 
months. In view of her K-ras wild type, she was stated on maintenance panitumumab and irinotecan 
and was doing well until the last follow-up. 
Discussion 
Here, we report a case of SBA with unexplained iron deficiency anemia despite 
extensive investigations for a year. The mass remained undetectable until the patient had 
a small bowel obstruction with metastatic disease involving the liver. A search of the US 
National Cancer Institute database has found 41.5% of cases of small bowel carcinoma 
which are similar in presentation and are diagnosed late as stage IV disease [8]. 
Several studies have reported that 6–12% of patients with occult gastrointestinal 
bleeding are diagnosed with small bowel tumors [4, 9]. These patients are usually 
asymptomatic and their symptoms constitute nonspecific abdominal discomfort and 
abdominal pain. Later, these patients develop small bowel obstruction, which is somewhat 
similar to the presentation of our patient [10]. In a study conducted by Hong et al. [10] 
(n = 22, 41.5%) patients diagnosed as stage IV SBA had a median survival of 4 months. 
No statistically significant difference was noted in terms of histological grade, site of 
primary tumor and tumor markers. One of the major limiting factors for poor prognosis 
in such cases is emergent laparotomy performed by a non-oncologic surgeon which 
makes optimal radical resection generally impossible. Studies have shown that suboptimal 
resection is associated with inaccurate pathological staging as well as with a poorer patient 
outcome [10]. Unfortunately most chemotherapy regimen achieve a low response rate 
with a minimal survival benefit. 
Several studies have explored the role of palliative chemotherapy in stage IV SBA. 
Hong et al. [10] have shown statistically significant survival in patients who received 
palliative chemotherapy (8 vs. 3 months) compared to those who did not receive 
chemotherapy (p = 0.025). Gibson et al. [11] have shown a response rate of 18.4% and a 
median overall survival of 8 months in a series of 39 patients. These patients received 
5-FU, adriamycin and mitomycin-C prospectively. More recently, a British study in 1998 
by Crawley et al. [12] reported 8 patients with advanced SBA treated with an infusion 
5-FU-based regimen. They found a response rate of 37.5% and a median survival of 13 
months. Fishman et al. [13] have shown a 30–40% response rate in patients who received 
gemcitabine and irinotecan-based regimen. 
From the limited clinical reports, the regimen of 5-FU with platinum compounds has 
been acknowledged as the first-line treatment for palliative chemotherapy in metastatic 
SBA [14]. Irinotecan has a good response in advanced SBA as second-line agent. Case Rep Oncol 2011;4:458–463 
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We noticed a response to chemotherapy for 6 months with FU-based regimen and a 
stable disease for another 6 months on second-line panitumumab (in view of K-ras wild 
type) and irinotecan and the patient is currently receiving the above regimen. 
Conclusion 
SBA remains a diagnostic challenge. Physician’s suspicion and awareness is crucial in 
making appropriate diagnostic investigations for earlier detection of SBA. This increases 
the chance of resection and hence survival. This is especially true in cases of unexplained 
iron deficiency anemia – an uncommon presentation – and in patients with abdominal 
pain of unknown cause. Moreover, patients with delayed diagnosis often have poorer 
prognosis. In this case, we have noticed a modest response to palliative chemotherapy 
with modified FU-based regimen (5-FU, folinic acid and oxaliplatin). We believe that 
further studies are needed to evaluate the possible application of newer investigative 
agents and treatment strategies to obtain a better outcome. 
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Fig. 1. CT Scan of abdomen with oral and IV contrast showing thickening of wall of the small 
intestine. 
 
 
 
Fig. 2. Small bowel follow-through with barium showing irregular filling defect in jejunum. 
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Fig. 3. Hematoxylin-eosin stain at 100× showing infiltrative small bowel adenocarcinoma with 
adjacent villous adenoma. 
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